In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.

@article{Soars2002InVA,
  title={In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.},
  author={Matthew G. Soars and Brian Burchell and Robert J. Riley},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2002},
  volume={301 1},
  pages={
          382-90
        }
}
The glucuronidation of a number of commonly used hepatic uridine diphosphate glucuronosyltransferase drug substrates has been studied in human tissue microsomes. Prediction of in vivo hepatic drug glucuronidation from liver microsomal data yielded a consistent 10-fold under-prediction. Consideration of protein binding was observed to be pivotal when predicting in vivo glucuronidation for acid substrates. Studies using human intestinal microsomes demonstrated the majority of drugs to be… 

Figures and Tables from this paper

Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats.

Using alamethicin-activated liver microsomes, incorporating f(u, mic) into CL(int, in vitro), and considering the contribution of glucuronidation may enable us to quantitatively predict in vivo hepatic glucuronidated from in vitro data.

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

Intestinal glucuronidation should be incorporated into clearance prediction, especially for compounds metabolised by intestine specific UGTs, as well as in vivo clearance prediction.

Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin

Use of in vitro data obtained in the presence of BSA and inclusion of renal clearance improved the IVIVE of glucuronidation clearance, with 50% of drugs predicted within 2-fold of observed values.

Quantitative Prediction of Human Intestinal Glucuronidation Effects on Intestinal Availability of UDP-Glucuronosyltransferase Substrates Using In Vitro Data

Combining the simplified intestinal availability model and in vitro conjugation assay make it possible to predict human FaFg regardless of UGT isoform, suggests results suggest.

Predictions of the In Vivo Clearance of Drugs from Rate of Loss Using Human Liver Microsomes for Phase I and Phase II Biotransformations

For highly bound drugs (>95% plasma protein bound), the addition of a plasma protein binding term increased the accuracy of the prediction of in vivo clearance, suggesting the substrate loss method may be used to accurately predict hepatic clearance of drugs.

Altered AZT glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: Comparison to hepatocytes and effect of incubation environment.

The goals of this work are to compare the enzyme kinetics for metabolism and inhibition of UGT2B7 using AZT as its substrate in human liver microsomes, recombinant UGT1B7 enzyme, and human hepatocytes, and to understand the effects different buffer systems have on the activity and kinetics of UHT7 as a possible explanation for the different kinetics observed in livermicrosomes versus intact cells.

Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development

It is proposed that the in vitro assessment should allow the evaluation of clearances for both transporter(s)-mediated uptake/excretion and metabolic degradation, and the assessment of hepatic uptake clearance as one of the kinetically important determinants for accurate predictions of hepatatic clearance in human.
...

References

SHOWING 1-10 OF 46 REFERENCES

Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney.

These preliminary studies indicated significant differences in the glucuronidation of xenobiotics by microsomes from the livers and kidneys of human and dog and should be confirmed using a larger panel of tissues from individual dogs.

Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  • R. Obach
  • Biology, Medicine
    Drug metabolism and disposition: the biological fate of chemicals
  • 1999
In the projection of human clearance values, basic and neutral compounds were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.

A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum.

The results indicate that compounds showing poor oral bioavailability can be excluded before in vivo pharmacokinetic study by using the serum incubation method, a convenient and useful tool at the early stage of drug discovery.

Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine.

  • M. MistryJ. Houston
  • Biology, Medicine
    Drug metabolism and disposition: the biological fate of chemicals
  • 1987
The glucuronidation of morphine, naloxone, and buprenorphine by the liver and intestine has been assessed both in vitro and in vivo in the rat, and a comparative approach to correlate in vivo and in vitro data has advantages over the use of absolute drug characteristics.

Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.

Under first-order conditions the activity of the hepatic drug-metabolizing enzymes may be closely approximated by the ratio of the in vitro kinetic constants Vmax and Km, which in turn is equivalent

Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.

Results suggest that glucuronidation, and specifically UGT1A1 activity, can profoundly contribute to intestinal first pass metabolism and interindividual variability due to the expression of common allelic variants.

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

A database containing information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquantitative prediction of the magnitude of potential interactions with drugs under development.

Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.

The results suggest that the glucuronidation of the pharmacologically active (S) enantiomer of oxazepam is decreased in a significant percentage of Caucasian individuals.

UDP-glucuronosyltransferases in human intestinal mucosa.